☰

Terrence L. Fisher, Ph.D. - Publications

Affiliations: 
2002 University of Rochester, Rochester, NY 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Greengard E, Williams R, Moriarity B, Liu X, Minard CG, Reid JM, Fisher T, Evans E, Pastore DR, Zauderer M, Voss S, Fox E, Weigel BJ. A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614). Pediatric Blood & Cancer. e30938. PMID 38520670 DOI: 10.1002/pbc.30938  0.351
2021 Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith ES, Mishra V, Schröder A, Chin K, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, et al. A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33820783 DOI: 10.1158/1078-0432.CCR-20-4792  0.341
2020 Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Sanborn RE, Spira AI, et al. Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies. Journal of Clinical Oncology. 38: 75-75. DOI: 10.1200/Jco.2020.38.5_Suppl.75  0.354
2020 Ruffolo LI, Ullman NA, Dale B, Jackson KM, Burchard P, Georger M, Jewell R, Belt BA, Galka E, Schoeniger LO, Mallow CL, Evans EE, Fisher TL, Zauderer M, Linehan D. Antibody blockade of semaphorin 4D to sensitize pancreatic cancer to immune checkpoint blockade. Journal of Clinical Oncology. 38: 26-26. DOI: 10.1200/Jco.2020.38.5_Suppl.26  0.417
2020 Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Sanborn RE, Spira AI, et al. Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 38: 3011-3011. DOI: 10.1200/Jco.2020.38.15_Suppl.3011  0.416
2020 Lowe MC, Olson B, Martinez A, Hammons J, Delman KA, Yushak ML, Allor M, Reilly CA, Mallow CL, Evans EE, Fisher TL, Lesinski GB, Kudchadkar RR. Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma. Journal of Clinical Oncology. 38: 10061-10061. DOI: 10.1200/Jco.2020.38.15_Suppl.10061  0.388
2020 Evans EE, Lesinski GB, Fisher TL, Mallow C, Olson B, Clavijo PE, Leonard JE, Pastore DR, Smith ES, Zauderer M, Allen CT, Lowe M, Kudchadkar R, Wu C, Steuer C, et al. Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Aacrahns19-A15  0.522
2019 Lowe MC, Lesinski GB, Delman KA, Yushak ML, Evans EE, Fisher TL, Kudchadkar RR. Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps9603  0.328
2019 Greengard EG, Williams RL, Liu X, Militano O, Fisher TL, Evans EE, Minard CG, Reid JM, Voss SD, Berg SL, Fox E, Weigel B. A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E21519  0.342
2019 Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Zauderer M, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Sanborn RE, Goldman JW. Preliminary results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC. Journal of Clinical Oncology. 37: 2601-2601. DOI: 10.1200/Jco.2019.37.15_Suppl.2601  0.323
2019 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Lesiniski G, Wu C, Hu-Lieskovan S, et al. Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr10  0.543
2019 Lesinski GB, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, Smith E, Zauderer M, Steuer C, Saba NF, Lowe M, Kudchadkar RR, Olson B, Wu C. Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors Clinical Trials. DOI: 10.1158/1538-7445.Sabcs18-Ct016  0.31
2019 Ruffolo LI, Jackson KM, Ullman N, Chacon A, Melucci A, Burchard P, Georger M, Jewell R, Prieto P, Belt B, Mallow C, Evans E, Fisher T, Zauderer M, Wu C, et al. Abstract B48: Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B48  0.463
2019 Shafique M, Fisher TL, Evans EE, Leonard JE, Pastore DR, Mallow C, Smith E, Zauderer M, Schröeder A, Chin K, Beck T, Baumgart M, Sanborn RE, Goldman JW. Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct086  0.377
2019 Evans EE, Fisher TL, Bussler H, Mallow C, Reilly C, Torno S, Pastore DR, Scrivens M, Howell A, Balch L, Leonard JE, Allen C, Clavijo PE, Lesinski G, Wu C, et al. Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies Cancer Research. 79: 1545-1545. DOI: 10.1158/1538-7445.Am2019-1545  0.538
2018 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Hu-Leiskovan S, Ribas A, et al. Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Pr09  0.525
2018 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard JE, Fisher T, Allen C, Clavijo PE, Lesinski G, Wu C, Hu-Lieskovan S, et al. Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy Cancer Research. 78: 1762-1762. DOI: 10.1158/1538-7445.Am2018-1762  0.493
2018 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard JE, Fisher TL, Allen C, Clavijo P, Hu-Lieskovan S, Ribas A, et al. Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B199  0.546
2017 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Comeau SR, Balch L, Knapp A, Leonard JE, Fisher TL, Hu-Lieskovan S, Ribas A, et al. Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies Cancer Research. 77: 3661-3661. DOI: 10.1158/1538-7445.Am2017-3661  0.528
2016 Evans EE, Bussler H, Torno S, Mallow C, Winters LA, Reilly C, Klimatcheva E, Veeraraghavan J, Jonason AS, Scrivens M, Kirk R, Howell A, Balch L, Leonard JE, Paris M, ... Fisher TL, et al. Abstract A119: Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates immune-mediated tumor rejection Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A119  0.532
2016 Evans EE, Bussler H, Mallow C, Reilly C, Torno S, Klimatcheva E, Scrivens M, Foster C, Howell A, Balch L, Knapp A, Leonard JE, Paris MJ, Fisher TL, Hu-Lieskovan S, et al. Abstract B023: Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B023  0.56
2016 Evans EE, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Leonard JE, Paris M, Fisher TL, Hu-Lieskovan S, et al. Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations Cancer Research. 76: 4888-4888. DOI: 10.1158/1538-7445.Am2016-4888  0.519
2015 Fisher TL, Seils J, Reilly C, Litwin V, Green L, Salkowitz-Bokal J, Walsh R, Harville S, Leonard JE, Smith E, Zauderer M. Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials. Cytometry. Part B, Clinical Cytometry. PMID 26566052 DOI: 10.1002/Cyto.B.21338  0.38
2015 Patnaik A, Weiss GJ, Leonard JE, Rasco D, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446947 DOI: 10.1158/1078-0432.Ccr-15-0431  0.371
2015 Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. Mabs. 0. PMID 26431358 DOI: 10.1080/19420862.2015.1102813  0.424
2015 Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M. Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody. Molecular Cancer Therapeutics. 14: 964-72. PMID 25657333 DOI: 10.1158/1535-7163.Mct-14-0924  0.363
2015 Evans EE, Jonason AS, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, ... Fisher TL, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research. 3: 689-701. PMID 25614511 DOI: 10.1158/2326-6066.Cir-14-0171  0.505
2015 Evans E, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Veeraraghavan J, Jonason AS, Leonard JE, ... ... Fisher TL, et al. Antibody blockade of Semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations F1000research. 4. DOI: 10.7490/F1000Research.1111176.1  0.408
2015 Evans EE, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva E, Winter LA, Kirk R, Howell A, Balch L, Veeraraghavan J, Jonason AS, Leonard JE, ... ... Fisher TL, et al. Antibody blockade of semaphorin 4D breaks down barriers to enhance tumoricidal immune infiltration and supports rational immunotherapy combinations Journal For Immunotherapy of Cancer. 3: 220. DOI: 10.1186/2051-1426-3-S2-P220  0.482
2015 Evans EE, Fisher TL, Edington C, Bussler H, Torno S, Jonason AS, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Pandina T, Mallow C, Kirk R, Howell A, et al. Abstract A67: Phase 1 study of VX15/2503, an immunomodulatory antibody to Semaphorin 4D that reverses tumor growth in preclinical studies Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A67  0.483
2015 Evans EE, Bussler H, Torno S, Mallow C, Winters LA, Reilly C, Klimatcheva K, Veeraraghavan J, Jonason AS, Scrivens M, Kirk R, Giralico S, Howell A, Leonard JE, Paris M, ... Fisher TL, et al. Abstract 278: Antibody blockade of semaphorin 4D promotes infiltration of activated tumor infiltrating leukocytes and reverses tumor growth Immunology. 75: 278-278. DOI: 10.1158/1538-7445.Am2015-278  0.411
2014 Smith ES, Jonason A, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, Marchi N, Janigro D, Argaw AT, Pham T, Seils J, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease. 73: 254-268. PMID 25461192 DOI: 10.1016/J.Nbd.2014.10.008  0.321
2014 Patnaik A, Ramanathan RK, Rasco DW, Weiss GJ, Campello-Iddison V, Eddington C, Fisher TL, Mutz D, Blaydorn L, Tolcher AW, Leonard JE. Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts). Journal of Clinical Oncology. 32: 3052-3052. DOI: 10.1200/Jco.2014.32.15_Suppl.3052  0.444
2014 Evans EE, Bussler H, Torno S, Veeraraghavan J, Jonason AS, Doherty MA, Reilly C, Mallow C, Seils J, Paris M, Fisher TL, Bowers WJ, Scrivens M, Balch L, Kirk R, et al. Abstract 5030: Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy Cancer Research. 74: 5030-5030. DOI: 10.1158/1538-7445.Am2014-5030  0.507
2013 Evans EE, Jonason AS, Paris M, Fisher TL, Torno S, Bussler H, Decker J, Scrivens M, Huang H, Winter LA, Pandina T, Balch L, Doherty MA, Kirk R, Howell A, et al. Abstract 1245: Reduction of tumor growth and metastasis by a humanized IgG4 monoclonal antibody to SEMA4D (VX15/2503). Cancer Research. 73: 1245-1245. DOI: 10.1158/1538-7445.Am2013-1245  0.492
2012 Cornelius CA, Fisher T, Seils J, Winter LA, Jonason AS, Smith E, Watkins R, Zauderer M, Leonard JE. Abstract 936: Nonclinical safety and pharmacology of VX15/2503: a humanized IgG4 monoclonal antibody to SEMA4D Cancer Research. 72: 936-936. DOI: 10.1158/1538-7445.Am2012-936  0.435
2011 Cornelius CA, Fisher T, Winter LA, Seils J, Reilly CA, Jonason AS, Smith ES, Watkins R, Zauderer M, Leonard JE. Nonclinical safety assessment of a humanized IgG4 anti-SEMA4D antibody to support clinical development. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13071. PMID 28019916 DOI: 10.1200/Jco.2011.29.15_Suppl.E13071  0.387
2011 Nasser AF, Budda B, Cornelius CA, Fisher T, Winter LA, Leonard JE. The role of pharmacokinetic (PK) modeling and simulations in selecting anti-SEMA4D antibody dose for phase I study in patients with advanced malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13072. PMID 28019915 DOI: 10.1200/Jco.2011.29.15_Suppl.E13072  0.33
2011 Cornelius CA, Fisher TL, Winter LA, Seils J, Reilly CA, Jonason AS, Smith E, Watkins R, Zauderer M, Leonard JE. Abstract 4578: Nonclinical safety assessment of VX15/2503: A humanized IgG4 monoclonal antibody to sema4D Cancer Research. 71: 4578-4578. DOI: 10.1158/1538-7445.Am2011-4578  0.338
2011 Jonason AS, Fisher TL, Torno S, Bussler H, Winter LA, Kirk R, Howell A, Caplan J, Kenney P, Reilly C, Scrivens M, Huang H, Croy L, Evans EE, Paris M, et al. Abstract 3667: Reduction of in vivo tumor growth and angiogenesis by a humanized IgG4 monoclonal antibody to SEMA4D Cancer Research. 71: 3667-3667. DOI: 10.1158/1538-7445.Am2011-3667  0.452
2010 Fisher T, Jonason A, Torno S, Bussler H, Li J, Evans EE, Watkins R, Zauderer M, Leonard JE, Smith ES. Antibody-mediated neutralization of Sema4D reduces tumor angiogenesis and growth in vivo. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E13154  0.37
2002 Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. The Prostate. 51: 153-65. PMID 11967950 DOI: 10.1002/Pros.10071  0.666
2001 Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Human Gene Therapy. 12: 1867-79. PMID 11589829 DOI: 10.1089/104303401753153929  0.624
2001 Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. Journal of Immunological Methods. 256: 107-19. PMID 11516759 DOI: 10.1016/S0022-1759(01)00436-7  0.615
2001 Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology. 102: 486-97. PMID 11328383 DOI: 10.1046/J.1365-2567.2001.01213.X  0.688
Show low-probability matches.